share_log

Wedbush Maintains Outperform on Immunic, Raises Price Target to $7

Benzinga ·  Oct 10, 2023 21:02

Wedbush analyst Andreas Argyrides maintains Immunic (NASDAQ:IMUX) with a Outperform and raises the price target from $5 to $7.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment